LAB Revenue Declines 7.6% As Standard BioTools Withdraws 2026 Outlook

• Standard BioTools reported a 7.6% year-over-year revenue decline to $20.1 million in the second quarter of 2026, driven by weakness in consumables and instruments.
• The company narrowed its adjusted EBITDA loss by 84% to $2.5 million, citing significant restructuring efforts and improved operational efficiency.
• Standard BioTools withdrew its full-year 2026 revenue outlook as it finalizes a merger with Treeline Biosciences and plans to divest its Mass Cytometry unit.
• Institutional investors remain engaged, with hedge funds increasing positions despite the earnings miss and cautious analyst sentiment.

Standard BioTools Inc. (NASDAQ: LAB) reported second-quarter 2026 financial results that reflect a transitional phase for the life sciences technology company. Revenue for the quarter fell to $20.1 million, representing a 7.6% decrease from the $21.76 million reported in the same period of the prior year. The decline was broad-based, impacting consumables, instruments, and services segments.

Top-line performance was pressured by lingering uncertainty in US academic spending. Consumables revenue dropped by 10%, while instruments revenue saw a 2% decline. Services revenue, which is predominantly composed of field services, decreased by 8% year-over-year to $5.6 million.

Despite the revenue contraction, the company demonstrated notable improvements in operational efficiency. Management highlighted that cost-cutting measures and restructuring actions have begun to positively impact profitability metrics. The company ended the quarter with a strong liquidity position, holding $541.1 million in cash and investments as of June 30, 2026.

How Did Operational Metrics Improve Despite Revenue Headwinds?

Standard BioTools achieved significant margin expansion during the quarter, driven by productivity gains and lower warranty costs. Gross margins expanded to approximately 52.4% on a GAAP basis, compared to 48.8% in the second quarter of 2025. On a non-GAAP basis, gross margins reached 56.3%, up from 54.1% in the prior year period.

Adjusted EBITDA for the quarter was a loss of $2.5 million, marking an 84% improvement from the $16.1 million loss recorded in the second quarter of 2025 . This improvement was primarily attributed to a 50% reduction in non-GAAP operating expenses, which fell to $13.8 million . The expense reduction was largely due to previously announced restructuring actions and lower incentive compensation .

However, the net loss from continuing operations widened to $21.5 million, or $0.12 per share on a GAAP basis . This increase was primarily driven by one-time transaction costs of $14.7 million associated with the pending merger with Treeline Biosciences . On a non-GAAP basis, the loss was $26.758 million, or $0.07 per share, an improvement from the $0.09 per share loss in the prior year .

The company also reported $2.8 million in restructuring charges during the quarter . Total operating expenses, including these one-time items, totaled $35.9 million, a slight decrease of 1% year-over-year . The inclusion of transaction costs in the GAAP results highlights the financial impact of the ongoing strategic restructuring .

What Is The Impact Of The Treeline Biosciences Merger On Outlook?

Standard BioTools has withdrawn its full-year 2026 revenue outlook due to the pending merger with Treeline Biosciences . The transaction is expected to close before the end of 2026, following a shareholder vote . The merger represents a major strategic shift, aiming to reshape the business profile and provide exposure to a well-capitalized pipeline .

As part of the transaction, Standard BioTools plans to divest its Mass Cytometry business . The deal also includes an early buyout of contingent payments by Illumina for $30 million . CEO Michael Egholm stated that the merger offers significant value creation opportunities and aligns with the company's long-term strategic goals .

The withdrawal of guidance complicates standalone financial projections for the remainder of the year . Analyst sentiment remains cautious, with a consensus "Reduce" rating and an average price target of $1.35 . The stock traded near its 12-month low of $0.70 following the earnings release, reflecting concerns over near-term execution .

Despite the earnings miss, institutional conviction remains notable. Hedge funds including Mak Capital One, Vanguard, State Street, and Millennium Management increased their positions in the fourth quarter . Mak Capital One led the buying activity, lifting its stake by 21.1% . Institutional investors collectively hold 53.74% of the shares, suggesting underlying confidence in the company's single-cell biology platforms .

The company's focus on cost optimization is intended to offset revenue headwinds and improve profitability metrics ahead of the anticipated transaction close . Standard BioTools continues to emphasize that non-GAAP measures are used to assess core operating performance by excluding items not indicative of ongoing business trends . The strong balance sheet provides a cushion as the company navigates this transition period .